AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
fallback

Uniglip M 1mg/500mg Tablet ER

Prescription Icon
Prescription Required

Marketer

Unimarck Healthcare Ltd

Salt Composition

Glimepiride (1mg) + Metformin (500mg)

Overview Uniglip M 1mg/500mg Tablet ER

Glimepiride/Metformin extended-release tablets (1mg/500mg) are classified as antidiabetic medications. This dual-drug formulation manages type 2 diabetes in adults by regulating blood glucose. Administer this medication with food, consistently at the same time daily for optimal efficacy. Dosage is determined by your physician and may adjust based on your blood sugar response. Continuous use is crucial; discontinuation without medical consultation risks elevated blood sugar, potentially leading to kidney complications, vision loss, neuropathy, and limb amputation. This medication is one component of a comprehensive diabetes management plan, encompassing dietary adjustments, regular exercise, and weight management as recommended by your doctor. Lifestyle choices significantly impact diabetes control. Hypoglycemia (low blood sugar) is a frequent adverse effect. Learn to identify symptoms like sweating, dizziness, headache, and tremors, and know how to counteract them with readily available glucose sources (e.g., sugary snacks or juice). Alcohol consumption should be minimized due to its potential to exacerbate hypoglycemia. Additional possible side effects include altered taste, nausea, diarrhea, abdominal pain, headache, and upper respiratory infections. Weight gain may occur in some patients. This medication is contraindicated for type 1 diabetes, diabetic ketoacidosis, and severe hepatic or renal impairment. Prior heart disease should be disclosed to your physician before initiating treatment. Pregnant or lactating individuals require medical consultation before use. Regular blood glucose monitoring is essential, along with potential blood tests to track blood cell counts and liver function.

Primary Ingredients of Uniglip M 1mg/500mg Tablet ER

No text provided. Please provide the text you wish me to rephrase.

Uses of Uniglip M 1mg/500mg Tablet ER

Managing type 2 diabetes

Major Benefits of Uniglip M 1mg/500mg Tablet ER:

Administer this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment period. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Consume Uniglip M 1mg/500mg Extended-Release Tablet with food.

Common Side effects of Uniglip M 1mg/500mg Tablet ER:

  • Headache
  • Hypoglycemia (low blood glucose level)
  • Nausea
  • Diarrhea

How to use Uniglip M 1mg/500mg Tablet ER:

Administer this medication precisely as your physician directs, adhering to the prescribed dosage and treatment schedule. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Consume Uniglip M 1mg/500mg Extended-Release Tablet with food.

How Uniglip M 1mg/500mg Tablet ER works:

Uniglip M ER tablets (1mg/500mg) combine glimepiride and metformin, two antidiabetic agents. Glimepiride, a sulfonylurea, enhances pancreatic insulin secretion to reduce blood sugar. Metformin, a biguanide, acts by decreasing hepatic glucose output, slowing intestinal glucose absorption, and improving insulin sensitivity.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Combining Uniglip M 1mg/500mg ER tablets with alcohol is not advisable due to safety concerns.

PregnancyPregnancyCONSULT YOUR DOCTOR

Extended-release Uniglip M 1mg/500mg tablets may pose risks during pregnancy. While human data is scarce, animal research indicates potential harm to a developing fetus. A physician will assess the potential advantages against any risks prior to prescription. Seek medical advice.

Breast feedingBreast feedingUNSAFE

Extended-release Uniglip M 1mg/500mg tablets are contraindicated for breastfeeding mothers. Evidence indicates potential infant harm from this medication.

DrivingDrivingCAUTION

Driving may be impaired by excessively low or high blood sugar levels. Refrain from driving if such symptoms arise.

KidneyKidneyCAUTION

Patients with kidney impairment should use Uniglip M 1mg/500mg Extended-Release tablets cautiously, potentially requiring dosage modification. Severe kidney disease contraindicates the use of Uniglip M 1mg/500mg Extended-Release tablets. Medical supervision, including regular kidney function assessments, is recommended during treatment.

LiverLiverCAUTION

Patients with liver impairment should use Uniglip M 1mg/500mg Extended-Release tablets cautiously, potentially requiring dosage modification. Consult a physician for guidance. For those with mild to moderate liver disease, initiating treatment with a low dose of Uniglip M 1mg/500mg Extended-Release tablets is generally recommended; however, its use is contraindicated in cases of severe hepatic dysfunction.

What if you forget to take Uniglip M 1mg/500mg Tablet ER :

Should you forget to take a Uniglip M 1mg/500mg Extended-Release tablet, administer it immediately upon remembrance. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.

Facts to Know About Uniglip M 1mg/500mg Tablet ER

LabelValue
Developing Habits No.
Treatment Category Diabetes Management

FAQs on Uniglip M 1mg/500mg Tablet ER

Store this medication in its original, tightly closed container, following the storage instructions on the label. Discard any unused medication and keep it out of reach of children, pets, and others.
Uniglip M 1mg/500mg Tablet ER can cause lactic acidosis, a serious medical emergency characterized by excessive blood lactic acid (also known as Metformin-associated lactic acidosis or MALA). This rare but dangerous side effect is more likely in patients with kidney disease, older adults, or those who consume large amounts of alcohol. Symptoms include muscle pain or weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and slow heart rate. If you experience these, stop taking Uniglip M 1mg/500mg Tablet ER and seek immediate medical attention.
Uniglip M 1mg/500mg Extended-Release tablets combine glimepiride and metformin to manage type 2 diabetes mellitus in adults. This combination improves blood glucose control when used with diet and exercise. Glimepiride stimulates insulin release from the pancreas, while metformin reduces liver glucose production and enhances insulin sensitivity. It's not suitable for type 1 diabetes.
Uniglip M 1mg/500mg Tablet ER may cause common side effects such as hypoglycemia, altered taste, nausea, stomach pain, diarrhea, and headache. Rare but serious side effects include lactic acidosis. Prolonged use can also result in vitamin B12 deficiency.
Prolonged use of Uniglip M 1mg/500mg ER tablets can lead to vitamin B12 deficiency by hindering its absorption. This deficiency, if left untreated, may result in anemia, neurological issues such as tingling, numbness in extremities, weakness, urinary problems, cognitive changes, and ataxia. To mitigate this risk, supplemental vitamin B12 is recommended at least annually by some researchers.
Uniglip M 1mg/500mg ER tablets can cause low blood sugar (hypoglycemia), manifesting as nausea, headache, irritability, hunger, sweating, dizziness, rapid heartbeat, anxiety, or shakiness. This risk increases with missed meals, alcohol consumption, excessive exercise, or concurrent use of other antidiabetic medications. Regular blood sugar monitoring is crucial. Carry a fast-acting sugar source, such as glucose tablets, honey, or fruit juice, at all times.
Combining Uniglip M 1mg/500mg ER tablets with alcohol is unsafe. Alcohol can lower blood sugar, potentially causing hypoglycemia, and increase the risk of lactic acidosis.
Uniglip M 1mg/500mg Table...
43
MRP 50
14% off